New blood pressure pill put to the test in UAE patients
NCT ID NCT07465666
First seen Jun 25, 2026 · Last updated Jul 23, 2026 · Updated 3 times
Summary
This study will look at how well a drug called ARNi (sacubitril/valsartan) lowers blood pressure in 500 adults with hypertension in the United Arab Emirates. Researchers will compare it to standard treatments like ACE inhibitors and calcium channel blockers. The goal is to see if ARNi works better in everyday medical practice, not just in controlled lab settings.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- sacubitril/valsartan (ARNi)
- What this could lead to
- If successful, this could show that ARNi is more effective than standard blood pressure medications for people in the UAE, potentially improving treatment guidelines.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be influenced by other factors. It is also limited to one region, so findings may not apply elsewhere.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a few short nights of sleep tip the scales toward high blood pressure?
- Chatbot could put blood pressure control in Patients' hands
- Can a 5-Step chat help tame high blood pressure?
- Can artery scans reveal hidden damage from high blood pressure?
- CRISPR injection could rewrite the future of blood pressure control
- Text messages and nurses: a new strategy to tackle hypertension in tanzania?